Description

WKYMVM (TFA) is a potent N-formyl peptide receptor (FPR1) and FPRL1/2 agonist, also activates several leukocyte effector functions such as chemotaxis, mobilization of complement receptor-3, and activation of the NADPH oxidase[1][2].—COVID-19-immunoregulation–C43H62F3N9O9S2—-[1]Christophe T, et al. The synthetic peptide Trp-Lys-Tyr-Met-Val-Met-NH2 specifically activates neutrophils through FPRL1/lipoxin A4 receptors and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2. J Biol Chem. 2001 Jun 15;276(24):21585-93.|[2]Christophe T, et al. Phagocyte activation by Trp-Lys-Tyr-Met-Val-Met, acting through FPRL1/LXA4R, is not affected by lipoxin A4. Scand J Immunol. 2002 Nov;56(5):470-6.–1313730-09-4–970.13—-CSCC[C@H](C(N)=O)NC([C@H](C(C)C)NC([C@H](CCSC)NC([C@H](CC1=CC=C(C=C1)O)NC([C@H](CCCCN)NC([C@H](CC2=CNC3=CC=CC=C23)N)=O)=O)=O)=O)=O.OC(C(F)(F)F)=O–Inflammation/Immunology–H2O–Formyl Peptide Receptor (FPR)—-GPCR/G Protein–Peptides